Crimson Publishers Publish With Us Reprints e-Books Video articles

Abstract

Global Journal of Endocrinological Metabolism

U-500 Insulin: An Effective Treatment for Patients with Type 2 Diabetes and Severe Insulin Resistance

  • Open or Close Nasser Mikhail*

    Department of Medicine, Endocrine Division, USA

    *Corresponding author: Nasser Mikhail, Department of Medicine, USA

Submission: February 20, 2019 Published: March 14, 2019

DOI: 10.31031/GJEM.2019.03.000552

ISSN 2637-8019
Volume3 Issue1

Abstract

Human regular insulin 500 (U-500) is a form of concentrated insulin that allows injection of high insulin doses with 5 times less volume compared with regular insulin. This concentrated insulin is indicated in patients with type 2 diabetes who require more than 200 units of insulin per day. Insulin U-500 displays both prandial and basal actions, and therefore can be injected as monotherapy in a convenient twicedaily regimen. Available data, mainly retrospective, suggest that insulin U-500 is effective, associated with better adherence, and decreased injection pain compared with non-concentrated insulins. Its main limitations are hypoglycemia and weight gain, and possibility of dosing errors. Randomized trials are needed to compare long-term efficacy and safety of insulin U-500 with other forms of insulin regimens.

Get access to the full text of this article


About Crimson

We at Crimson Publishing are a group of people with a combined passion for science and research, who wants to bring to the world a unified platform where all scientific know-how is available read more...

Leave a comment

Contact Info

  • Crimson Publishers, LLC
  • 555 Madison Avenue, 5th floor
  •     New York, NY 10022, USA
  • +1 (929) 600-8049
  • +1 (929) 447-1137
  • info@crimsonpublishers.com
  • www.crimsonpublishers.com